2025.07.07本文字数:4287,阅读时长大约10.8分钟导读:艾伯维以21亿美元收购Capstan Therapeutics,凸显体内CAR-T技术的巨大潜力与市场价值。云顶新耀凭借其AI+mRNA技术平台,研发进度与Capstan同步,股价逆势大涨,其体内CAR-T疗法及mRNA平台正成为全球关注焦点。艾伯维又一次让市场看到了体内CAR-T(in vivo CAR-T)的热度。6月30日...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.